Bringing Clarity to Clinical Decisions
Early detection remains essential to improving outcomes for bladder cancer patients.
Yair Lotan, MD
Professor of Urology, Chief of Urologic Oncology, Jane and John Justin Distinguished Chair in Urology, in Honor of Claus G. Roehrborn, M.D. at the University of Texas Southwestern Medical Center, Vice-Chair of Clinical Affairs in the Department of Urology, Head of the Clinical Research Office and Medical Director of the Urology Clinic at UT Southwestern and Parkland Health and Hospital System
Yair Lotan, MD
Scientific Advisory Board, Vesica Health
Dr. Lotan is the co-chair of the Harold C. Simmons Comprehensive Cancer Center disease-oriented team for urologic cancers. He is a member of UT Southwestern’s Clinical Research Planning Group and the Tissue Bank Steering Committee and Cancer Committee. Dr. Lotan is a member of the AUA Bladder Cancer Guidelines and an editorial reviewer for many medical periodicals, including the Journal of Urology, European Urology, Cancer, Urologic Oncology, and the British Journal of Urology International. He is an active member of multiple professional organizations including the American Urological Association (AUA), Society of Urologic Oncology (SUO), International Bladder Cancer Group (IBCG), and the Bladder Cancer Advocacy Network (BCAN).
Â
Dr. Lotan is internationally known for his research on urine markers and molecular markers, which will help determine which patients are at higher risk for recurrent cancer. He is also involved in health economics research, which evaluates the cost-effectiveness of surgery and cancer prevention. Dr. Lotan is currently the lead investigator in multiple clinical trials related to the detection and treatment of bladder cancer and has previously led numerous trials in bladder cancer.
